JP2016510343A - ラキニモドを用いる多発性硬化症の治療 - Google Patents

ラキニモドを用いる多発性硬化症の治療 Download PDF

Info

Publication number
JP2016510343A
JP2016510343A JP2015558130A JP2015558130A JP2016510343A JP 2016510343 A JP2016510343 A JP 2016510343A JP 2015558130 A JP2015558130 A JP 2015558130A JP 2015558130 A JP2015558130 A JP 2015558130A JP 2016510343 A JP2016510343 A JP 2016510343A
Authority
JP
Japan
Prior art keywords
laquinimod
multiple sclerosis
subject
progressive multiple
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015558130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510343A5 (enExample
Inventor
タルシック，ノラ
バール−ゾハール，ダン
ハヤルデニイ，リアット
ギルガン・シェルキ、ヨッシ
ゴルフィネ，タリイ
ナペリッツ，フォルカー
ゾラーニ，エラ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016510343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2016510343A publication Critical patent/JP2016510343A/ja
Publication of JP2016510343A5 publication Critical patent/JP2016510343A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
JP2015558130A 2013-02-15 2014-02-13 ラキニモドを用いる多発性硬化症の治療 Pending JP2016510343A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US61/765,394 2013-02-15
US201361911106P 2013-12-03 2013-12-03
US61/911,106 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (2)

Publication Number Publication Date
JP2016510343A true JP2016510343A (ja) 2016-04-07
JP2016510343A5 JP2016510343A5 (enExample) 2017-03-16

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558130A Pending JP2016510343A (ja) 2013-02-15 2014-02-13 ラキニモドを用いる多発性硬化症の治療

Country Status (18)

Country Link
US (2) US20140235670A1 (enExample)
EP (1) EP2956137A4 (enExample)
JP (1) JP2016510343A (enExample)
KR (1) KR20150119227A (enExample)
CN (1) CN105163737A (enExample)
AU (1) AU2014216199A1 (enExample)
BR (1) BR112015019564A2 (enExample)
CA (1) CA2900503A1 (enExample)
CL (1) CL2015002181A1 (enExample)
EA (1) EA201591507A1 (enExample)
HK (2) HK1218254A1 (enExample)
IL (1) IL240014A0 (enExample)
MX (1) MX2015010296A (enExample)
PE (1) PE20151526A1 (enExample)
SG (1) SG11201505818WA (enExample)
TW (1) TW201442709A (enExample)
UY (1) UY35328A (enExample)
WO (1) WO2014127139A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515530A (ja) * 2017-03-26 2020-05-28 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA2964315A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
WO2022011155A1 (en) * 2020-07-09 2022-01-13 Oklahoma Medical Research Foundation Biomarkers for identifying relapses in multiple sclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
US20120142730A1 (en) * 2010-12-07 2012-06-07 Nora Tarcic Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
US20130028866A1 (en) * 2011-07-28 2013-01-31 Yossi Gilgun Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
CN101466379B (zh) * 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
MX2015004564A (es) * 2012-10-12 2015-07-21 Teva Pharma Laquinimod para producir el daño talamico en la esclerosis multiple.
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
US20120142730A1 (en) * 2010-12-07 2012-06-07 Nora Tarcic Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
US20130028866A1 (en) * 2011-07-28 2013-01-31 Yossi Gilgun Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THE LANCET, 2008, VOL. 371, NO. 9630, P. 2085-2092, JPN6017037181, ISSN: 0003650160 *
THE NEW ENGLAND JOURNAL OF MEDICINE, 2012, VOL. 366, NO. 11, P. 1000-1009, JPN6017037178, ISSN: 0003650159 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
JP2020515530A (ja) * 2017-03-26 2020-05-28 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
JP2023022174A (ja) * 2017-03-26 2023-02-14 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
JP2024153882A (ja) * 2017-03-26 2024-10-29 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
US12343371B2 (en) 2017-03-26 2025-07-01 Mapi Pharma Ltd. Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate
JP7802122B2 (ja) 2017-03-26 2026-01-19 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム

Also Published As

Publication number Publication date
MX2015010296A (es) 2016-05-05
HK1218254A1 (zh) 2017-02-10
HK1218251A1 (zh) 2017-02-10
TW201442709A (zh) 2014-11-16
US20140235670A1 (en) 2014-08-21
EP2956137A1 (en) 2015-12-23
KR20150119227A (ko) 2015-10-23
IL240014A0 (en) 2015-09-24
BR112015019564A2 (pt) 2017-07-18
US20180064702A1 (en) 2018-03-08
WO2014127139A1 (en) 2014-08-21
EA201591507A1 (ru) 2015-12-30
AU2014216199A1 (en) 2015-09-03
PE20151526A1 (es) 2015-11-20
CA2900503A1 (en) 2014-08-21
UY35328A (es) 2014-09-30
CL2015002181A1 (es) 2016-06-03
EP2956137A4 (en) 2016-08-03
CN105163737A (zh) 2015-12-16
SG11201505818WA (en) 2015-08-28

Similar Documents

Publication Publication Date Title
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
US20180064702A1 (en) Treatment of progressive forms of multiple sclerosis with laquinimod
JP2017200927A (ja) ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療
KR20170109091A (ko) 라퀴니모드를 이용한 다발경화증의 치료
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
JP2015533163A (ja) 多発性硬化症における視床損傷を低減するためのラキニモド
US20160235735A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
JP2017514824A (ja) 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
WO2025068949A1 (en) Emrusolmin for use in treating multiple system atrophy
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180522